RelA Antibody

Rabbit Polyclonal
Antigen Affinity Purified

Catalog No. A301-824A
Lot No. A301-824A-2

Protein ID NP_068810.2
GeneID 5970

APPLICATIONS	WB, IP, IHC, ChIP-Seq
SPECIES REACTIVITY	Human, Mouse
AMOUNT	100 µl
CONCENTRATION	1000 µg/ml
STORAGE/SHELF LIFE	2 - 8° C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09% Sodium Azide
ISOTYPE	IgG
ORIGIN	USA
PRODUCTION PROCEDURES	Antibody was affinity purified using an epitope specific to RelA immobilized on solid support. The epitope recognized by A301-824A maps to a region between residue 501 and 551 of human reticuloendotheliosis viral oncogene homolog A using the numbering given in entry NP_068810.2 (GeneID 5970). Immunoglobulin concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.
APPLICATIONS	Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

Western Blot	1:2,000 - 1:10,000
Immunoprecipitation	2 - 5 µg/mg lysate
Immunohistochemistry	1:500 - 1:2,000. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.
ChIP-Seq	ChIP-Seq 4 µg/30 µg chromatin

APPLICATION NOTES	Western blot of immunoprecipitates performed using Normal Pig Serum (Cat. No. S100-020), Goat anti-Rabbit Light Chain HRP Conjugate (Cat. No. A120-113P) and 4-20% SDS-PAGE (link to IP-western blot protocol in Additional Info section below). Western blot of lysates performed using standard western blot reagents and 4-20% SDS-PAGE.
IHC HUMAN CONTROLS	Breast Carcinoma, Glioblastoma, Ovarian Carcinoma, Prostate Carcinoma
ADDITIONAL INFO	https://www.bethyl.com/product/A301-824A Use the link above to view SDS, a current list of citations, and other product specific information. IP-western blot protocol: https://www.bethyl.com/content/protocol_IP_WB

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Eric McIntush, PhD | Chief Scientific Officer Date: June 21, 2019



Detection of human and mouse RelA/p65 by western blot (h&m) and immunoprecipitation (h). *Samples:* Whole cell lysate from HeLa (15 and 50 µg for WB; 1 mg for IP, 20% of IP loaded), HEK293T (T; 50 µg), Jurkat (J; 50 µg) and mouse NIH 3T3 (M; 50 µg) cells. *Antibodies:* Affinity purified rabbit anti-RelA/p65 antibody A301-824A (lot A301-824A-2) used for WB at 0.1 µg/ml (A) and 0.4 µg/ml (B) and used for IP at 3 µg/mg lysate. RelA/p65 was also immunoprecipitated by a previous lot (lot A301-824A-1) of this antibody. *Detection:* Chemiluminescence with exposure times of 30 seconds (A) and 10 seconds (B).



Detection of human RelA/p65 by immunohistochemistry. *Sample:* FFPE section of human breast carcinoma. *Antibody:* Affinity purified rabbit anti-RelA/p65 (Cat. No. A301-824A Lot2) used at a dilution of 1:1,000 (1µg/ml). *Detection:* DAB



Localization of RelA Binding Sites by ChIP-sequencing. Chromatin from human ependymoma tumor was immunoprecipitated with anti-RelA antibody A301-824A and analyzed by DNA sequencing. The figure illustrates the peak distribution of RelA binding within a 250 Kb region of chromosome 19 as detected using anti-RelA A301-824A. ChIP-seq validation performed by Active Motif, Carlsbad, CA.